Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
246 studies found for:    sirolimus cancer | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Condition: Refractory Hurthle Cell Thyroid Cancer
Interventions: Drug: sorafenib;   Drug: everolimus
22 Recruiting A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: LEE011;   Drug: everolimus
23 Recruiting Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Carboplatin;   Drug: Everolimus
24 Recruiting A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007
Condition: Advanced Solid Tumors, Non-small Cell Lung Cancer
Intervention: Drug: AMG 479, Everolimus, Panitumumab
25 Recruiting Aging Mammary Stem Cells and Breast Cancer Prevention
Condition: Cancer of Breast
Intervention: Drug: Rapamycin
26 Recruiting A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Sirolimus
27 Recruiting UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone
Condition: Thyroid Cancer
Interventions: Drug: Lenvatinib;   Drug: Everolimus
28 Not yet recruiting Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation
Conditions: Malignant Neoplasm of Breast;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Neoplasms of Uncertain or Unknown Behavior
Interventions: Drug: Neratinib;   Drug: Everolimus;   Drug: Palbociclib;   Drug: Trametinib
29 Recruiting Palbociclib With Everolimus + Exemestane In BC
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Hormone Receptor (HR)-Positive Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Everolimus;   Drug: Exemestane
30 Recruiting PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
Condition: Metastatic Renal Cancer
Intervention: Drug: Prednisone + Everolimus
31 Recruiting Women's Triple-Negative First-Line Study: Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
32 Recruiting Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: LEE011;   Drug: Exemestane;   Drug: Everolimus
33 Not yet recruiting Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer
Conditions: Malignant Neoplasms of Female Genital Organs;   Endometrial Carcinoma
Interventions: Drug: Ribociclib;   Drug: Everolimus;   Drug: Letrozole
34 Recruiting Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
Condition: Cancer
Interventions: Drug: Sirolimus;   Drug: Celecoxib;   Drug: Etoposide;   Drug: Cyclophosphamide
35 Recruiting Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor-negative;   Stage IV Breast Cancer;   Triple-negative Breast Carcinoma
Interventions: Drug: everolimus;   Drug: eribulin mesylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
36 Recruiting PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Conditions: Sarcoma;   Malignant Peripheral Nerve Sheath Tumors
Interventions: Drug: PLX3397;   Drug: Sirolimus
37 Recruiting Study of GnRH-A (Leuprorelin) Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus(afinitor);   Drug: Letrozole;   Drug: Leuprolide
38 Recruiting A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Condition: Desmoid Tumor
Intervention: Drug: Sirolimus
39 Recruiting Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
Condition: Triple Negative Breast Cancer
Interventions: Drug: Everolimus;   Drug: Eribulin
40 Recruiting Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
Conditions: Primary Non-metastatic Breast Cancer;   Who Remain Disease-free
Interventions: Drug: Everolimus;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.